

# Elena K Schneider-Futschik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/499758/publications.pdf>

Version: 2024-02-01

56  
papers

1,404  
citations

304743

22  
h-index

377865

34  
g-index

58  
all docs

58  
docs citations

58  
times ranked

1846  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 212-219.	0.7	19
2	Ivacaftor Alters Macrophage and Lymphocyte Infiltration in the Lungs Following Lipopolysaccharide Exposure. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 419-428.	4.9	3
3	The health impacts of ambient air pollution in Australia: a systematic literature review. <i>Internal Medicine Journal</i> , 2021, 51, 1567-1579.	0.8	8
4	Advantages and Disadvantages of Using Magnetic Nanoparticles for the Treatment of Complicated Ocular Disorders. <i>Pharmaceutics</i> , 2021, 13, 1157.	4.5	32
5	Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7606.	4.1	15
6	Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis. <i>Frontiers in Pharmacology</i> , 2021, 12, 577263.	3.5	6
7	Entry of cystic fibrosis transmembrane conductance potentiator ivacaftor into the developing brain and lung. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 857-864.	0.7	13
8	Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, e97-e109.	5.6	69
9	Editorial: Functional Characterization and Pharmaceutical Targets in Common and Rare CFTR Dysfunctions. <i>Frontiers in Physiology</i> , 2021, 12, 830285.	2.8	0
10	Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of <i>in Vitro</i> Pharmacology and Clinical Translation. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 4-10.	4.9	25
11	Synthesis and structure-activity relationships of teixobactin. <i>Annals of the New York Academy of Sciences</i> , 2020, 1459, 86-105.	3.8	26
12	Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 2247-2258.	4.1	17
13	Multiple Reaction Monitoring Mass Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in Cystic Fibrosis: A High-Throughput Method. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 987-996.	4.9	17
14	The Balance between the Safety of Mother, Fetus, and Newborn Undergoing Cystic Fibrosis Transmembrane Conductance Regulator Treatments during Pregnancy. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 835-843.	4.9	15
15	Magnetic Nanoparticle-Based Drug Delivery Approaches for Preventing and Treating Biofilms in Cystic Fibrosis. <i>Magnetochemistry</i> , 2020, 6, 72.	2.4	8
16	Effective Strategy Targeting Polymyxin-Resistant Gram-Negative Pathogens: Polymyxin B in Combination with the Selective Serotonin Reuptake Inhibitor Sertraline. <i>ACS Infectious Diseases</i> , 2020, 6, 1436-1450.	3.8	20
17	The Killing Mechanism of Teixobactin against Methicillin-Resistant <i>Staphylococcus aureus</i> : an Untargeted Metabolomics Study. <i>MSystems</i> , 2020, 5, .	3.8	33
18	Metabolomic Description of Ivacaftor Elevating Polymyxin B Mediated Antibacterial Activity in Cystic Fibrosis <i>Pseudomonas aeruginosa</i> . <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 433-443.	4.9	27

#	ARTICLE	IF	CITATIONS
19	Health impacts of bushfire smoke exposure in Australia. <i>Respirology</i> , 2020, 25, 495-501.	2.3	53
20	Polymyxins Bind to the Cell Surface of Unculturable <i>Acinetobacter baumannii</i> and Cause Unique Dependent Resistance. <i>Advanced Science</i> , 2020, 7, 2000704.	11.2	31
21	Successes and Challenges: Inhaled Treatment Approaches Using Magnetic Nanoparticles in Cystic Fibrosis. <i>Magnetochemistry</i> , 2020, 6, 25.	2.4	13
22	The impact of backbone N <sup>ε</sup> -methylation on the structure-activity relationship of Leu 10 <sup>ε</sup> -teixobactin. <i>Journal of Peptide Science</i> , 2019, 25, e3206.	1.4	6
23	Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis. <i>Gene Therapy</i> , 2019, 26, 354-362.	4.5	23
24	Traffic pollution near childcare centres in Melbourne. <i>Australian and New Zealand Journal of Public Health</i> , 2019, 43, 410-412.	1.8	5
25	Predictive factors for lumacaftor/ivacaftor clinical response. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 368-374.	0.7	56
26	Molecular Mechanisms of Neurotoxicity Induced by Polymyxins and Chemoprevention. <i>ACS Chemical Neuroscience</i> , 2019, 10, 120-131.	3.5	45
27	Contemporary Anti-Ebola Drug Discovery Approaches and Platforms. <i>ACS Infectious Diseases</i> , 2019, 5, 35-48.	3.8	3
28	Rapamycin Confers Neuroprotection against Colistin-Induced Oxidative Stress, Mitochondria Dysfunction, and Apoptosis through the Activation of Autophagy and mTOR/Akt/CREB Signaling Pathways. <i>ACS Chemical Neuroscience</i> , 2018, 9, 824-837.	3.5	67
29	The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites. <i>ERJ Open Research</i> , 2018, 4, 00127-2017.	2.6	21
30	Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis <i>Pseudomonas aeruginosa</i> Isolates and Their Interactions with Sputum Biomolecules. <i>ACS Infectious Diseases</i> , 2018, 4, 646-655.	3.8	19
31	Broad activity of diphenylethidium analogues against <i>Mycobacterium tuberculosis</i> , malaria parasites and bacterial pathogens. <i>European Journal of Medicinal Chemistry</i> , 2018, 148, 507-518.	5.5	14
32	Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor. <i>Drug Metabolism Letters</i> , 2018, 12, 71-74.	0.8	36
33	Mechanistic Insights From Global Metabolomics Studies into Synergistic Bactericidal Effect of a Polymyxin B Combination With Tamoxifen Against Cystic Fibrosis MDR <i>Pseudomonas aeruginosa</i> . <i>Computational and Structural Biotechnology Journal</i> , 2018, 16, 587-599.	4.1	19
34	Exploiting Macromolecular Design To Optimize the Antibacterial Activity of Alkylated Cationic Oligomers. <i>Biomacromolecules</i> , 2018, 19, 4629-4640.	5.4	14
35	A Comparative Study of Outer Membrane Proteome between Paired Colistin-Susceptible and Extremely Colistin-Resistant <i>Klebsiella pneumoniae</i> Strains. <i>ACS Infectious Diseases</i> , 2018, 4, 1692-1704.	3.8	15
36	Magnetic Nanoparticles Coated with a Thermosensitive Polymer with Hyperthermia Properties. <i>Polymers</i> , 2018, 10, 10.	4.5	59

#	ARTICLE	IF	CITATIONS
37	Plasma Protein Binding Structure-Activity Relationships Related to the N-Terminus of Daptomycin. <i>ACS Infectious Diseases</i> , 2017, 3, 249-258.	3.8	20
38	A traceless reversible polymeric colistin prodrug to combat multidrug-resistant (MDR) gram-negative bacteria. <i>Journal of Controlled Release</i> , 2017, 259, 83-91.	9.9	15
39	From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators. <i>Microbial Drug Resistance</i> , 2017, 23, 640-650.	2.0	45
40	Cationic acrylate oligomers comprising amino acid mimic moieties demonstrate improved antibacterial killing efficiency. <i>Journal of Materials Chemistry B</i> , 2017, 5, 531-536.	5.8	38
41	Aminoglycoside Concentrations Required for Synergy with Carbapenems against <i>Pseudomonas aeruginosa</i> Determined via Mechanistic Studies and Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	31
42	Gelofusine Ameliorates Colistin-Induced Nephrotoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	18
43	Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	11
44	Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes. <i>ACS Infectious Diseases</i> , 2017, 3, 606-619.	3.8	25
45	Hydrolyzable Poly[Poly(Ethylene Glycol) Methyl Ether Acrylate]-Colistin Prodrugs through Copper-Mediated Photoinduced Living Radical Polymerization. <i>Bioconjugate Chemistry</i> , 2017, 28, 1916-1924.	3.6	11
46	Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 130-141.	4.7	33
47	A Fresh Shine on Cystic Fibrosis Inhalation Therapy: Antimicrobial Synergy of Polymyxin B in Combination with Silver Nanoparticles. <i>Journal of Biomedical Nanotechnology</i> , 2017, 13, 447-457.	1.1	12
48	Antibiotic-non-antibiotic combinations for combating extremely drug-resistant Gram-negative "superbugs". <i>Essays in Biochemistry</i> , 2017, 61, 115-125.	4.7	71
49	A Portrait of the Sialyl Glycan Receptor Specificity of the H10 Influenza Virus Hemagglutinin: A Picture of an Avian Virus on the Verge of Becoming a Pandemic?. <i>Vaccines</i> , 2017, 5, 51.	4.4	5
50	A Novel Chemical Biology Approach for Mapping of Polymyxin Lipopeptide Antibody Binding Epitopes. <i>ACS Infectious Diseases</i> , 2016, 2, 341-351.	3.8	16
51	The Plasma Protein Binding Proteome of Ertapenem: A Novel Compound-Centric Proteomic Approach for Elucidating Drug-Plasma Protein Binding Interactions. <i>ACS Chemical Biology</i> , 2016, 11, 3353-3364.	3.4	7
52	Deficiency in Outer Dense Fiber 1 Is a Marker and Potential Driver of Idiopathic Male Infertility. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 3685-3693.	3.8	30
53	Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1038, 57-62.	2.3	39
54	An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI. <i>ACS Infectious Diseases</i> , 2016, 2, 478-488.	3.8	80

#	ARTICLE	IF	CITATIONS
55	Molecular Characterisation of the Haemagglutinin Glycan-Binding Specificity of Egg-Adapted Vaccine Strains of the Pandemic 2009 H1N1 Swine Influenza A Virus. <i>Molecules</i> , 2015, 20, 10415-10434.	3.8	6
56	Drug-drug plasma protein binding interactions of ivacaftor. <i>Journal of Molecular Recognition</i> , 2015, 28, 339-348.	2.1	34